Moreover, a higher percentage of terminal exhausted TIM‐3+ LAG‐3+ PD‐1+ CAR T cells derived from CLL patients was observed compared to those derived from ALL patients (Figure S8D). This evidence concerns the gene LAG3 and acute lymphoblastic leukemia.